Table of Contents Author Guidelines Submit a Manuscript
Computational and Mathematical Methods in Medicine
Volume 2013 (2013), Article ID 358980, 6 pages
http://dx.doi.org/10.1155/2013/358980
Research Article

Mathematical Model of Dynamic Protein Interactions Regulating p53 Protein Stability for Tumor Suppression

1Mathematical Sciences, Georgia Southern University, Statesboro, GA 30458, USA
2Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Received 11 July 2013; Revised 8 December 2013; Accepted 9 December 2013

Academic Editor: Henggui Zhang

Copyright © 2013 Hua Wang and Guang Peng. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Vogelstein and K. W. Kinzler, “Cancer genes and the pathways they control,” Nature Medicine, vol. 10, no. 8, pp. 789–799, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. D. W. Meek, “Tumour suppression by p53: a role for the DNA damage response?” Nature Reviews Cancer, vol. 9, no. 10, pp. 714–723, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Momand, D. Jung, S. Wilczynski, and J. Niland, “The MDM2 gene amplification database,” Nucleic Acids Research, vol. 26, no. 15, pp. 3453–3459, 1998. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Wade, Y. V. Wang, and G. M. Wahl, “The p53 orchestra: Mdm2 and Mdmx set the tone,” Trends in Cell Biology, vol. 20, no. 5, pp. 299–309, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. Haupt, R. Maya, A. Kazaz, and M. Oren, “Mdm2 promotes the rapid degradation of p53,” Nature, vol. 387, no. 6630, pp. 296–299, 1997. View at Publisher · View at Google Scholar · View at Scopus
  6. M. H. G. Kubbutat, S. N. Jones, and K. H. Vousden, “Regulation of p53 stability by Mdm2,” Nature, vol. 387, no. 6630, pp. 299–303, 1997. View at Publisher · View at Google Scholar · View at Scopus
  7. J.-P. Kruse and W. Gu, “Modes of p53 regulation,” Cell, vol. 137, no. 4, pp. 609–622, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Alarcon-Vargas and Z. Ronai, “p53-Mdm2-the affair that never ends,” Carcinogenesis, vol. 23, no. 4, pp. 541–547, 2002. View at Google Scholar · View at Scopus
  9. J. K. Murray and S. H. Gellman, “Targeting protein-protein interactions: lessons from p53/MDM2,” Biopolymers, vol. 88, no. 5, pp. 657–686, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. D. L. Waning, J. A. Lehman, C. N. Batuello, and L. D. Mayo, “Controlling the Mdm2-Mdmx-p53 circuit,” Pharmaceuticals, vol. 3, no. 5, pp. 1576–1593, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. K. W. Kohn, “Molecular interaction map of the mammalian cell cycle control and DNA repair systems,” Molecular Biology of the Cell, vol. 10, no. 8, pp. 2703–2734, 1999. View at Google Scholar · View at Scopus
  12. R. Butler and G. P. Bates, “Histone deacetylase inhibitors as therapeutics for polyglutamine disorders,” Nature Reviews Neuroscience, vol. 7, no. 10, pp. 784–796, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Sczaniecka, K. Gladstone, S. Pettersson, L. McLaren, A.-S. Huart, and M. Wallace, “MDM2 protein-mediated ubiquitination of NUMB protein: identification of a second physiological substrate of MDM2 that employs a dual-site docking mechanism,” Journal of Biological Chemistry, vol. 287, no. 17, pp. 14052–14068, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Sui, E. B. Affar, Y. Shi et al., “Yin Yang 1 is a negative regulator of p53,” Cell, vol. 117, no. 7, pp. 859–872, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. J. F. Chau, D. Jia, Z. Wang et al., “A crucial role for bone morphogenetic protein-Smad1 signalling in the DNA damage response,” Nature Communications, vol. 3, article 836, 2012. View at Google Scholar
  16. S. Maheswaran, C. Englert, P. Bennett, G. Heinrich, and D. A. Haber, “The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis,” Genes and Development, vol. 9, no. 17, pp. 2143–2156, 1995. View at Google Scholar · View at Scopus
  17. T. K. MacLachlan, R. Takimoto, and W. S. El-Deiry, “BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targets,” Molecular and Cellular Biology, vol. 22, no. 12, pp. 4280–4292, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Möller, H. Sirma, T. G. Hofmann et al., “PML is required for homeodomain-interacting protein kinase 2 (HIPK2)-mediated p53 phosphorylation and cell cycle arrest but is dispensable for the formation of HIPK domains,” Cancer Research, vol. 63, no. 15, pp. 4310–4314, 2003. View at Google Scholar · View at Scopus
  19. X. Liu and R. L. Erikson, “Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 10, pp. 5789–5794, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. D. P. Silver and D. M. Livingston, “Mechanisms of BRCA1 tumor suppression,” Cancer Discovery, vol. 2, no. 8, pp. 679–684, 2012. View at Google Scholar
  21. D. L. Burkhart and J. Sage, “Cellular mechanisms of tumour suppression by the retinoblastoma gene,” Nature Reviews Cancer, vol. 8, no. 9, pp. 671–682, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. F. Chung, L. Lu, and V. Vu, “Spectra of random graphs with given expected degrees,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 11, pp. 6313–6318, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. R. Horn and C. Johnson, Matrix Analysis, Cambridge University Press, Cambridge, UK, 1999.
  24. B. Bollabos, Modern Graph Theory, Springer, New York, NY, USA, 1998.
  25. J. Jurkin, G. Zupkovitz, S. Lagger et al., “Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis,” Cell Cycle, vol. 10, no. 3, pp. 406–412, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Haberland, R. L. Montgomery, and E. N. Olson, “The many roles of histone deacetylases in development and physiology: implications for disease and therapy,” Nature Reviews Genetics, vol. 10, no. 1, pp. 32–42, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Ropero and M. Esteller, “The role of histone deacetylases (HDACs) in human cancer,” Molecular Oncology, vol. 1, no. 1, pp. 19–25, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. L. C. Cantley and B. G. Neel, “New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 8, pp. 4240–4245, 1999. View at Publisher · View at Google Scholar · View at Scopus
  29. A. di Cristofano and P. P. Pandolfi, “The multiple roles of PTEN in tumor suppression,” Cell, vol. 100, no. 4, pp. 387–390, 2000. View at Google Scholar · View at Scopus
  30. B. T. Hennessy, D. L. Smith, P. T. Ram, Y. Lu, and G. B. Mills, “Exploiting the PI3K/AKT pathway for cancer drug discovery,” Nature Reviews Drug Discovery, vol. 4, no. 12, pp. 988–1004, 2005. View at Publisher · View at Google Scholar · View at Scopus